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A randomized prospective multicenter trial for 
stroke prevention by prophylactic surgical 
closure of the left atrial appendage in patients 
undergoing bioprosthetic aortic valve 
sur ger y––LAA-CLOSURE trial protocol 
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Patients undergoing surgical aortic valve replacement (SAVR) are at high risk for atrial fibrillation (AF) and stroke after surgery. 
There is an unmet clinical need to improve stroke prevention in this patient population. The LAA-CLOSURE trial aims to assess 
the efficacy and safety of prophylactic surgical closure of the left atrial appendage for stroke and cardiovascular death 
prevention in patients undergoing bioprosthetic SAVR. This randomized, open-label, prospective multicenter trial will enroll 
1,040 patients at 13 European sites. The primary endpoint is a composite of cardiovascular mortality, stroke and systemic 
embolism at 5 years. Secondary endpoints include cardiovascular mortality, stroke, systemic embolism, bleed fulfilling aca- 
demic research consortium (BARC) criteria, hospitalization for decompensated heart failure and health economic evaluation. 
Sample size is based on 30% risk reduction in time to event analysis of primary endpoint. Prespecified reports include 30-day 
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safety analysis focusing on AF occurrence and short-term outcomes and interim analyses at 1 and 3 years for primary and 
secondary outcomes. Additionally, substudies will be performed on the completeness of the closure using transesophageal 






















































































Stroke is a frequent long-term adverse event after aor-
tic valve replacement surgery (SAVR) affecting up to 7%
to 15% of patients at 5 year follow-up. 1 , 2 Given the high
burden of atrial fibrillation (AF) after SAVR, emboli re-
lated to AF are likely a major source of these strokes and
stroke is often the first manifestation of AF. 2 , 3 Thus, there
is an unmet clinical need for better stroke prevention in
this patient population. 
Based on previous studies ≥90% of AF-related left atrial
thrombi are located in the left atrial appendage (LAA), 4
and therefore, LAA occlusion is a tempting method for
AF-related stroke prevention in SAVR patients. A slew of
observational or underpowered randomized controlled
trial data suggests at least 30% stroke risk reduction af-
ter cardiac surgery with LAA closure, both at 30 days af-
ter surgery as well as in long-term. 5-11 Among elderly pa-
tients with AF undergoing coronary bypass, mitral valve
or aortic valve surgery, concomitant surgical LAA occlu-
sion was associated with a lower risk of readmission for
thromboembolism over 3 years when compared with no
LAA occlusion. 11 A recent small underpowered random-
ized trial suggested up to 70% risk reduction in a compos-
ite of post-operative symptomatic ischemic stroke, tran-
sient ischemic attack, or imaging findings of silent cere-
bral ischemic lesions during the median follow-up of 3.7
years irrespective of AF status at enrollment. 12 
Currently, the evidence is insufficient to support rou-
tine LAA occlusion during SAVR for AF patients or those
at high AF risk postoperatively. The main challenge is to
ensure an adequate and durable LAA occlusion with min-
imal additional risk for patients using sutures, ligation,
stapler or specific occlusion devices. EACTS guidelines
suggest that devices designed for appendage exclusion
should be used rather than a cut-and-sew or stapling tech-
nique. 13 Recommendations are based on the findings of
meta-analysis of 5 clinical trials including one random-
ized controlled trial enrolling approximately 1,400 pa-
tients with LAA occlusion. 13 Of the 5 studies, only one
showed a statistical benefit for LAA occlusion, with 3 giv-
ing neutral results and one demonstrating an increased
risk. 13 Challenges in achieving adequate LAA occlusion
based on postoperative transesophageal echocardiogra-
phy may explain this heterogeneity. 14 The highest suc-
cess rate was 93% but most studies have reported only a
55% to 66% rates of successful occlusion when using a
variety of methods including stapling, ligation and ampu-
tation. The best results have been obtained using devices
specifically designed for this purpose. 13 Another challenge is whether the proper patient pop-
ulation can be identified. Approximately 25% of patients
undergoing SAVR have preoperative paroxysmal or per-
manent AF, however, up to 70% of patients have had at
least one episode of AF by the end of first postoperative
year. 15 Thus, patients undergoing SAVR have a high post-
operative AF burden compared to other types of cardiac
surgery such as coronary bypass. Moreover, stroke rates
increase with higher CHA 2 DS 2 -VASc scores 16 and thus it
is reasonable to target this enduring treatment for high-
risk individuals who may encounter silent AF episodes
later in life. 
In the LAA-CLOSURE trial, we aim to assess the efficacy
and safety of prophylactic surgical closure of LAA in a
large-scale randomized controlled clinical trial in SAVR
patients at increased thromboembolic risk, but without
prior AF (paroxysmal, persistent or permanent) or other
indication for oral anticoagulation therapy at the time of
surgery. 
Materials and Methods 
Type and design 
This randomized, prospective, open-label, multicenter
trial aims to enroll 1,040 patients undergoing aortic valve
replacement with a bioprosthesis. At the time of enroll-
ment, included subjects must have CHA 2 DS 2 -VASC score
≥2, no history of AF nor indication for permanent anti-
coagulation. Patients are randomized in 1:1 ratio to stan-
dard therapy + surgical closure of LAA vs standard ther-
apy alone. 
This is an investigator-initiated academic trial, which
received an unrestricted research grant from AtriCure ltd
(Mason, OH, USA) covering part of the budget. Other
funding sources include Finnish Medical Foundation,
Finnish Foundation for Cardiovascular Health, and Turku
University Hospital Research Foundation. The authors
are solely responsible for the design and conduct of this
study, all study analyses, the drafting and editing of the
paper and its final contents. All the publication rights in-
cluding decision to submit the manuscript for publica-
tion remain among investigators. Turku University Hos-
pital (Turku, Finland) is the coordinating site of the trial.
Interventions 
‘Standard aortic valve replacement ± concomitant
surgery’ refers to aortic valve replacement with a
bioprosthesis according to indications in the current
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Figure 1 
Flow chart of the LAA-CLOSURE trial. Standard surgery refers to aortic valve replacement according to clinical indications defined in 
ESC/EACTS guidelines for the management of valvular heart disease. BARC, Bleeding Academic Research Consortium criteria; CABG, 


















ESC/EACTS guidelines for the management of valvular
heart disease 12 ( Control group ). The operation as well
as the pre- and postoperative care will be performed ac-
cording to local surgical policies. ‘Standard aortic valve
replacement ± concomitant surgery with LAA occlu-
sion’ ( Active treatment group ) refers the same opera-
tion and care as above and surgical closure of LAA us-
ing an AtriClip device. All the sites are used to perform
Atriclip placement and we do not have a formal roll-in
period.  
Inclusion and exclusion criteria 
Inclusion cr iter ia are: (1) Patients undergoing surgical
aortic valve replacement ( + /- coronary bypass AND/OR
mitral valve surgery) according to clinical indications
(ESC/EACTS guidelines for the management of valvular
heart disease); (2) Age ≥18 years; (3) No indication for
long term anticoagulation at the time of enrollment; (4)
CHA 2 DS 2 -VASC score ≥2; (5) Patient is willing to com-
ply with specified follow-up evaluations; (6) Patient or
legally authorized representative has been informed of





















































































the nature of the study, agrees to its provisions and has
provided written informed consent, approved by the ap-
propriate Medical Ethics committee or Institutional Re-
view Board. We include bicuspid aortic valve patients but
not those undergoing any aortic root procedure 
Exclusion cr iter ia include: (1) Age < 18 years; (2) Ex-
pected survival < 1 year; (3) History of AF; (4) Indica-
tion for long term anticoagulation therapy before the in-
dex procedure; (5) Mechanical valve implantation previ-
ously or at the index procedure; (6) Any significant med-
ical condition, which in the Investigator’s opinion may
interfere with the patient’s optimal participation in the
study. 
Randomization and blinding 
Upon receipt of the signed written informed consent
and satisfactory documentation showing that the patient
meets all inclusion and does not meet exclusion cr iter ia,
the investigator will open a sealed envelope in numeri-
cal order. These envelopes are produced by independent
statistician by using https://www.sealedenvelope.com
randomization algorithm. There is a stratified block ran-
domization (block size of 10) according to participating
center, that is, allocation will be assigned according to a
pre-defined randomization list. In each block 5 and 5 pa-
tients are randomized to surgical closure of LAA and no
closure groups, respectively, in each center. Patients are
randomized prior surgical procedure. Patients are consid-
ered randomized as soon as the envelope is opened and
treatment allocation given. 
Endpoints 
Primary endpoint is a composite endpoint of stroke,
systemic embolism and cardiovascular death at 5 years.
Secondary endpoints include each of the following: car-
diovascular death, stroke and transient ischemic attack
(TIA), hospitalization for acute decompensated heart fail-
ure, major bleeding according to Bleeding Academic Re-
search Consortium criteria (BARC 3a, b, c, or 5), any
bleeding (BARC 1, 2 3a, b, c, or 5) and surgery-related
bleeding (BARC 4). 17 Net adverse events include both
the primary composite endpoint and major BARC bleeds.
An adjudication committee will adjudicate all the events.
Definitions of endpoints 
Cardiovascular death 
The primary cause as defined here is the underlying
disease or injury that initiated the train of events result-
ing in death. It includes deaths that result from an acute
myocardial infarction, sudden cardiac death, death due
to heart failure, death due to stroke, death due to cardio-
vascular procedures, death due to cardiovascular hemor-
rhage, and death due to other cardiovascular causes. Stroke 
Stroke is defined as an acute episode of focal or global
neurological dysfunction caused by brain, spinal cord, or
retinal vascular injury as a result of hemorrhage or infarc-
tion. 
Ischemic stroke is defined as an acute episode of focal
cerebral, spinal, or retinal dysfunction caused by infarc-
tion of central nervous system tissue. Hemorrhage may
be a consequence of ischemic stroke. In this situation,
the stroke is an ischemic stroke with hemorrhagic trans-
formation and not a hemorrhagic stroke. 
Hemorrhagic stroke is defined as an acute episode of
focal or global cerebral or spinal dysfunction caused by
intraparenchymal, intraventricular, or subarachnoid hem-
orrhage. 
Undetermined stroke is defined as an acute episode of
focal or global neurological dysfunction caused by pre-
sumed brain, spinal cord, or retinal vascular injury as a
result of hemorrhage or infarction but with insufficient
information to allow categorization as either ischemic or
hemorrhagic. 
The diagnoses of stroke, TIA and systemic embolism
will be confirmed from the patient records, as diagnosed
by the treating neurologist. Only a stroke and TIA con-
sidered as definite by the treating neurologist will be in-
cluded for adjudication. 
The modified Rankin Scale is used to address stroke
disability. 
TIA 
TIA is defined as a transient ( < 24 hours) episode of
focal neurological dysfunction caused by brain, spinal
cord, or retinal ischemia, without acute infarction. 
Systemic embolism 
Systemic embolism is defined as an acute vascular oc-
clusion of an extremity or organ, documented by means
of imaging, surgery, or autopsy. 
Major bleeding (BARC criteria 3 and 5) 17 
BARC 3a refers to (1) overt bleeding plus hemoglobin
drop of 3 to 5 g/dL ∗ (provided hemoglobin drop is re-
lated to bleed); (2) any transfusion with overt bleeding.
BARC 3b refers to (1) overt bleeding plus hemoglobin
drop > 5 g/dL ∗ (provided hemoglobin drop is related
to bleed); (2) cardiac tamponade; (3) bleeding requir-
ing surgical intervention for control (excluding den-
tal/nasal/skin/hemorrhoid);(4) Bleeding requiring intra-
venous vasoactive agents. BARC 3c refers to (1) intracra-
nial hemorrhage (does not include microbleeds or hem-
orrhagic transformation, does include intraspinal); (2)
Subcategories confirmed by autopsy or imaging or lum-
bar puncture; (3) intraocular bleed compromising vision.
BARC 5 refers to fatal bleeding. 
Hospitalization for heart failure 
For the endpoint of hospitalization for acute decom-
pensated heart failure, a patient is required to have an
unscheduled hospital admission for a primary diagnosis
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of heart failure with a length of stay that either exceeds
24 hours or crosses a calendar day (if hospital admission
and discharge times are unavailable). The patient is also
required to have typical signs, symptoms, and diagnos-
tic testing results consistent with the diagnosis of heart
failure. Laboratory findings consistent with heart failure
including elevated natriuretic peptides, radiological ev-
idence of congestion, and either echocardiographic or
invasive evidence of elevated filling pressures. In addi-
tion to these signs and symptoms, the patient should
also receive treatment specifically directed at heart fail-
ure, including at least one of the following: (1) signifi-
cant augmentation in oral diuretic therapy; (2) initiation
of intravenous diuretic (even a single dose) or vasoac-
tive agent (eg, vasodilator, vasopressor, or inotropic ther-
apy); or (3) mechanical circulatory support or fluid re-
moval. Significant augmentation of oral diuretic therapy
is defined, for example, as the doubling of loop diuretic
dose; initiation of maintenance loop diuretic therapy; or
initiation of combination diuretic therapy to relieve con-
gestion. Combination diuretic therapy could include: (1)
a thiazide-type diuretic (eg, hydrochlorothiazide, metola-
zone, or chlorothiazide) plus a loop diuretic; or (2) a min-
eralocorticoid receptor antagonist (eg, spironolactone or
eplerenone) plus a loop diuretic. Mechanical fluid re-
moval includes ultrafiltration, hemofiltration, and dialysis
as well as thoracentesis or paracentesis for heart failure
management. 
Anticoagulation therapy 
After index surgery, patients are treated according to
local practice guidelines as they were treated without
surgical closure of LAA. Decisions on the medical ther-
apy remain at the treating physician’s discretion. Patients
allocated to surgical closure of LAA will not be routinely
advised to avoid long-term anticoagulation. 
Prespecified trial reporting schedules 
– 30 days 
– 1 year 
– 5 years (main results) 
– 10 years if applicable 
Prespecified substudies 
We have two pre-specified substudies on completeness
of LAA closure using transesophageal echocardiography
or cardiac computed tomography; and AF occurrence in
7-day ECG-holter 1 year after index surgery. The Core labs
for both imaging substudy and 7-day ECG-holter study are
at Turku University Hospital/University of Turku. These
substudies enroll at selected sites. Alternatives for imag-
ing include transesophageal echocardiography or cardiac
CT depending on site’s preference. Study sites 
1. Turku University Hospital and University of Turku,
Finland 
2. St. Antonius ziekenhuis, Nieuwegein, Netherlands 
3. Hospital Clinico Universitario de Valladolid, Val-
ladolid, Spain 
4. Karolinska University Hospital and The Karolinska
Institutet, Stockholm, Sweden 
5. Sahlgrenska University Hospital, Gothenburg, Swe-
den 
6. Medisch Spectrum Twente, Enschede, Netherlands 
7. K uopio University Hospital, Kuopio, Finland 
8. Central Clinical Hospital of the Ministry of the Inte-
rior and Administration in Warsaw, Warsaw, Poland 
9. Skåne University Hospital and Lund University,
Lund, Sweden 
10. Hospital Universitario La Princesa, Madrid, Spain 
11. Asklepios Klinik Harburg, Hamburg, Germany 
12. Medizinische Hochschule, Hannover, Germany 
13. University Medical Center Rotterdam, Rotterdam,
Netherlands 
Enrollment schedule 
The LAA-CLOSURE trial multicenter enrollment began
in November 2018. Anticipated end of enrollment is late
2021. Follow-ups for the main results (5 years) will be
completed by February 2026. Study reporting will be
started 2022. 
Statistical analysis 
One recent small underpowered randomized trial sug-
gested a hazard ratio (HR) 0.3 (95% CI: 0.1–0.8, P = .02)
for treatment effect of LAA closure, while a nonrandom-
ized large registry showed HR 0.67 (95% CI, 0.56-0.81;
P < .001) in 2.6 year follow-up. 12 Moreover, when focus-
ing on patients with CHA 2 DS 2 -VASC score ≥2, the stroke
rate lies between 1.35 and 4.93/100 patient years irre-
spective of preoperative or in-hospital AF. 16 We antici-
pate a clinically significant 30% risk reduction in the pri-
mary endpoint with the occlusion of the LAA. Sample
size calculation assumed 109 (21%) primary endpoint
event rate in the control group at 5 years (alpha was
set to 0.05 and beta 0.90). This was based on the data
from STS database as well as pilot data from Turku Uni-
versity Hospital. 1 , 2 In the general population, the share
of cardioembolic strokes is 25% to 30%. However, in pa-
tients who have undergone SAVR, the rate of cardioem-
bolic stroke is 48% at a median follow-up of 5 years. 2
Therefore, 520 patients (10% dropout rate) are needed
per group, and altogether 1,040 patients will be random-
ized. 
We will perform all analyses in the total population us-
ing the intention-to-treat method. We will calculate HRs,
95% confidence intervals, and P values for time-to-event
analyses using a Cox proportional-hazards model with



























































































the stratification factor as a covariate. All analyses will be
performed using appropriate statistical software such as
R statistics software (R Foundation for Statistical Comput-
ing, Vienna, Austria) and SPSS software package (SPSS,
Inc., Chicago, Illinois, USA). 
Discussion 
LAA-CLOSURE trial is one of the largest randomized tri-
als on surgical closure of the LAA. The prophylactic ap-
proach of the trial focuses on the high AF-risk and stroke-
risk patients who will likely encounter AF later in life.
Trial is powered to show 30% risk reduction in the pri-
mary endpoint of stroke, systemic embolism and cardio-
vascular death at 5-year follow-up after SAVR. Secondary
clinical outcomes will assess the potential additional ben-
efits and harms of the procedure such as the risk for de-
compensated heart failure, bleeds and AF. Prespecified
substudies will assess the achieved completeness of clo-
sure and occurrence of AF later in life. 
Stroke is a frequent and often deleterious long-term ad-
verse event after SAVR. Observational data suggest 7%
to 15% rates of stroke at 5-year follow-up. 1 , 2 The rate,
however, is highly comorbidity-related and it increases
with higher CHA 2 DS 2 -VASc scores 16 . Therefore, we tar-
geted this trial in high stroke-risk patients as defined
by CHA 2 DS 2 -VASc score ≥2. Roughly half of strokes af-
ter SAVR are considered cardioembolic and often AF-
related. 2 New-onset AF (NOAF) is common after SAVR
with an incidence of 31% to 74%. 18-24 NOAF is often
considered only a temporar y, surger y-associated phe-
nomenon, but recent evidence suggests that at least half
of the patients with NOAF encounter AF also later in
life. 15 AF is often silent in these elderly patients leading to
delayed diagnosis and initiation of oral anticoagulation. 3
Based on this background prophylactic closure of LAA
could provide stroke protection in this clinical scenario,
since LAA is the principal origin of thromboembolism in
AF. 
Occlusion of LAA may provide stroke protection
already shortly after surgery. In intermediate to high
surgical-risk patients, 30-day stroke rate in a randomized
trial was as high as 6.1%. 25 Early after SAVR, patients
are in a prothrombotic state related to the operation,
immobilization, and swelling caused by fluid reten-
tion. 26 , 27 Moreover, the initiation of vitamin K antagonist
therapy may suppress levels of protein C and S, 28 and
increase the risk of thromboembolic complications.
Therefore, more efficacious means of preventing throm-
boembolic complications are needed in this clinical
setting. 
It is still debatable whether oral anticoagulation can be
avoided in patients with LAA occlusion and novel data
are needed in this area. ESC/EACTS guidelines for the
management of AF do not recommend discontinuation
of oral anticoagulation in patients with LAA occlusion. 29This recommendation derives from data that showed the
inability to achieve acceptably high rates of successful
occlusion on post-operative transesophageal echocardio-
graphy. 13 Nevertheless, cardiac computed tomography
data on the study device AtriClip shows favorable closure
result. 30 , 31 LAA-CLOSURE trial has a substudy addressing
the completeness of closure result. Selected sites enroll
patients for transesophageal echocardiography or cardiac
computed tomography to assess the closure result at 3
months after index surgery. 
LAA-CLOSURE trial includes patients with or without
concomitant CABG and/or mitral valve surgery to mimic
real-life SAVR patient population. Concomitant mitral
valve surgery may increase the risk of postoperative AF.
However, patients with concomitant ascending aortic
surgery are excluded because of the risk of emboli origi-
nating from the aorta. 
Observational study suggested an increased risk for AF
after LAA occlusion. 32 Thus, it is important that LAA-
CLOSURE trial will address this observation using clini-
cal follow-up of AF occurrence at 3, 12, 24, 36, 48, and
60 months after surgery. In addition, a 7-day ECG-holter
substudy is performed in selected sites. These data will
provide information not only on temporal risk but also
incidence and persistence of AF after SAVR and LAA oc-
clusion – significant for planning of future trials on the
topic. 
Finally, percutaneous LAA occlusion using specific
devices in three randomized controlled trials have
demonstrated that patients undergoing the procedure
have similar risk of stroke when compared with those
on oral anticoagulation (warfarin or non-vitamin K an-
tagonist oral anticoagulant) in the prevention of stroke
in nonvalvular AF, with reductions in hemorrhagic
stroke and both cardiovascular and all-cause death in
over 3-year follow-up. 33 The concept of successful LAA
occlusion for stroke prevention, therefore, seems to
be of similar efficacy to oral anticoagulation – the best
current prevention for AF-related thromboembolic com-
plications, but the efficacy and safety of surgical LAA
occlusion need to be explored. 
In conclusion, the LAA-CLOSURE trial aims to provide
data on a clinically meaningful way to reduce strokes
and cardiovascular deaths in patients at high stroke-risk
scheduled for SAVR. 
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